Ovidrel Injection

Anovulatory infertility, Adjunct to IVF procedures and other assisted conception techniques, Induction of Ovulation & Pregnancy

Induction of Ovulation & Pregnancy 250 mcg SC one day following the last dose of follicle-stimulating agent; use only after adequate follicular development has been determined; hold treatment if there is an excessive ovarian response

Hypersensitivity to component Primary ovarian failure Uncontrolled thyroid or adrenal dysfunction Uncontrolled organic intracranial lesion such as pituitary tumor Undiagnosed abnormal uterine bleeding Ovarian cyst or enlargement of undetermined origin Sex hormone dependent tumor of reproductive tract and accessory organs Pregnancy

Potent gonadotropic substance capable of causing ovarian hyperstimulation syndrome (OHSS) in women with or without pulmonary or vascular complications Withhold where clinically significant ovarian enlargement or excessive estradiol production to reduce risk of ovarian hyperstimulation syndrome Safe and effective induction of ovulation and use of prefilled syringe in women requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis Ovarian hyperstimulation syndrome is characterized by mild to moderate ovarian enlargement may occur, accompanied by abdominal distension and/or abdominal pain; usually regresses without treatment in 2-3 wk; may progress rapidly to a serious medical event characterized by dramatic increase in vascular permeability, which may result in rapid fluid accumulation in peritoneal cavity, thorax and/or pericardium Potential for arterial thromboembolism Risk of enlargement of preexisting ovarian cysts or rupture of ovarian cysts with resultant hemoperitoneum If ovaries are abnormally enlarged on last day of FSH therapy, choriogonadotropin alfa should not be administered in this course of therapy; this will reduce risk of development of ovarian hyperstimulation syndrome Early warning signs of development of OHSS are severe pelvic pain, nausea, vomiting, and weight gain; symptomatology seen with cases of OHSS include abdominal pain, abdominal distension, gastrointestinal symptoms including nausea, vomiting and diarrhea, severe ovarian enlargement, weight gain, dyspnea,and oliguria Clinical evaluation may reveal hypovolemia, hemoconcentration, electrolyte imbalances, ascites, hemoperitoneum, pleural effusions, hydrothorax, acute pulmonary distress, and thromboembolic events Transient liver function test abnormalities suggestive of hepatic dysfunction, which may be accompanied by morphologic changes on liver biopsy, reported in association with ovarian hyperstimulation syndrome OHSS may be more severe and

Not Classi Pregnancy Intrauterine death and impaired parturition observed in pregnant rats given a dose of urinary-hCG (500 IU) equivalent to three times maximum human dose of 10,000 USP, based on body surface area Lactation Not known whether this drug is excreted in human milk; because many drugs are excreted in human milk, exercise caution if hCG administered to a nursing woman The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breastfed child from therapy or from underlying maternal condition

1-10% Ovarian cyst (3%),Ovarian hyperstimulation (2-3%),Abdominal pain (3-4%),Nausea (3%),Vomiting (3%),Injection site inflammation (<2%) <1% Breast pain,Cervical lesion,Cough,Albuminuria,Back pain,Breast pain,Cardiac arrhythmia,Dizziness,Emotional lability,Genial herpes,Hyperglycemia,Pruritus,Urinary tract infection,Vaginal hemorrhage,Vaginitis

Choriogonadotropin alfa is a recombinant form of chorionic gonadotrophin. Its effects mimic those of leuteinizing hormone, which triggers ovulation and formation of the corpus luteum in women and stimulates the production of testosterone by the testes in men. Produced by recombinant DNA techniques: human chorionic gonadotropin; stimulates late follicular maturation & resumption of oocyte meiosis & initiates rupture of pre-ovulatory ovarian follicle

Ovidrel 250 mcg/0.5 ml Injection manufactured by Janata Pharma. Its generic name is Choriogonadotropin Alfa.